{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:17:49Z","timestamp":1780445869920,"version":"3.54.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11695-023-06986-5","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T20:02:17Z","timestamp":1702584137000},"page":"456-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of Predictors of Non-alcoholic Steatohepatitis and Its Severity in Individuals Undergoing Bariatric Surgery"],"prefix":"10.1007","volume":"34","author":[{"given":"Arthur Balestra Silveira","family":"Ayres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carollyne Rodovalho Guerra","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martinho Antonio","family":"Gestic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murillo Pimentel","family":"Utrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe David Mendon\u00e7a","family":"Chaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Callejas-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinton Adami","family":"Chaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5804-1580","authenticated-orcid":false,"given":"Everton","family":"Cazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"6","key":"6986_CR1","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1053\/gast.2002.33573","volume":"122","author":"JM Clark","year":"2002","unstructured":"Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122(6):1649\u201357.","journal-title":"Gastroenterology"},{"issue":"11","key":"6986_CR2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686\u201390.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"6986_CR3","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005\u201323.","journal-title":"Hepatology"},{"issue":"3","key":"6986_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2174\/1570161115666170621075619","volume":"16","author":"N Katsiki","year":"2018","unstructured":"Katsiki N, Perez-Martinez P, Anagnostis P, et al. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol. 2018;16(3):219\u201327.","journal-title":"Curr Vasc Pharmacol"},{"issue":"8","key":"6986_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","volume":"65","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109\u201323.","journal-title":"Metabolism"},{"issue":"22","key":"6986_CR6","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.3748\/wjg.v21.i22.6820","volume":"21","author":"VG Athyros","year":"2015","unstructured":"Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol. 2015;21(22):6820\u201334.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"6986_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/HCO.0000000000000068","volume":"29","author":"N Katsiki","year":"2014","unstructured":"Katsiki N, Athyros VG, Karagiannis A, et al. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol. 2014;29(4):389\u201395.","journal-title":"Curr Opin Cardiol"},{"key":"6986_CR8","doi-asserted-by":"publisher","first-page":"A10","DOI":"10.1016\/j.metabol.2018.08.003","volume":"87","author":"N Katsiki","year":"2018","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease and colorectal cancer: a marker of risk or common causation? Metabolism. 2018;87:A10\u20133.","journal-title":"Metabolism"},{"key":"6986_CR9","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","volume":"111S","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154170.","journal-title":"Metabolism"},{"issue":"8","key":"6986_CR10","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","volume":"65","author":"A Lonardo","year":"2016","unstructured":"Lonardo A, Sookoian S, Pirola CJ, et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2016;65(8):1136\u201350.","journal-title":"Metabolism"},{"issue":"1","key":"6986_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12876-017-0696-4","volume":"17","author":"N Wongjarupong","year":"2017","unstructured":"Wongjarupong N, Assavapongpaiboon B, Susantitaphong P, et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2017;17(1):149.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"6986_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/17474124.2019.1580143","volume":"13","author":"J Chen","year":"2019","unstructured":"Chen J, Bian D, Zang S, et al. The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. Expert Rev Gastroenterol Hepatol. 2019;13(4):385\u201395.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"6986_CR13","doi-asserted-by":"publisher","first-page":"e0226351","DOI":"10.1371\/journal.pone.0226351","volume":"15","author":"JM Lee","year":"2020","unstructured":"Lee JM, Park YM, Yun JS, et al. The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: national population-based cohort study. PLoS One. 2020;15(1):e0226351.","journal-title":"PLoS One"},{"issue":"1","key":"6986_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"11","key":"6986_CR15","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1007\/s10620-015-3728-3","volume":"60","author":"JZ Zhu","year":"2015","unstructured":"Zhu JZ, Dai YN, Wang YM, et al. Prevalence of nonalcoholic fatty liver disease and economy. Dig Dis Sci. 2015;60(11):3194\u2013202.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"6986_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1463-1326.2008.00926.x","volume":"11","author":"MH Ahmed","year":"2009","unstructured":"Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2009;11(3):188\u201395.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"6986_CR17","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1080\/00365520500264953","volume":"40","author":"JW Haukeland","year":"2005","unstructured":"Haukeland JW, Konopski Z, Linnestad P, et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2005;40(12):1469\u201377.","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"6986_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1590\/1516-3180.2016.0306311216","volume":"135","author":"E Cazzo","year":"2017","unstructured":"Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J. 2017;135(3):277\u201395.","journal-title":"Sao Paulo Med J"},{"issue":"2","key":"6986_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/hep.23521","volume":"51","author":"P Angulo","year":"2010","unstructured":"Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology. 2010;51(2):373\u20135.","journal-title":"Hepatology"},{"issue":"8","key":"6986_CR20","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1007\/s11695-021-05429-3","volume":"31","author":"LS Jimenez","year":"2021","unstructured":"Jimenez LS, Marques RA, Gestic MA, et al. Non-invasive markers in non-alcoholic fatty liver disease: reliability is variable according to BMI status. Obes Surg. 2021;31(8):3888\u201392.","journal-title":"Obes Surg"},{"issue":"6","key":"6986_CR21","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/hep.510300604","volume":"30","author":"P Angulo","year":"1999","unstructured":"Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356\u201362.","journal-title":"Hepatology"},{"issue":"2","key":"6986_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s11695-019-04179-7","volume":"30","author":"TB de Freitas Diniz","year":"2020","unstructured":"de Freitas Diniz TB, de Jesus RN, Jimenez LS, et al. Non-alcoholic fatty liver disease is associated with impairment of ejection fraction among individuals with obesity undergoing bariatric surgery: results of a cross-sectional study. Obes Surg. 2020;30(2):456\u201360.","journal-title":"Obes Surg"},{"issue":"4","key":"6986_CR23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801.","journal-title":"J Hepatol"},{"key":"6986_CR24","doi-asserted-by":"publisher","first-page":"154333","DOI":"10.1016\/j.metabol.2020.154333","volume":"114","author":"N Katsiki","year":"2021","unstructured":"Katsiki N, Mantzoros C. Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)\/DASH (dysmetabolism associated steatohepatitis). Metabolism. 2021;114:154333.","journal-title":"Metabolism"},{"issue":"1","key":"6986_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"issue":"2","key":"6986_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/antiox10020270","volume":"10","author":"L Rinaldi","year":"2021","unstructured":"Rinaldi L, Pafundi PC, Galiero R, et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A Narrative Review. Antioxidants (Basel). 2021;10(2):270.","journal-title":"Antioxidants (Basel)"},{"issue":"8","key":"6986_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW Wong","year":"2018","unstructured":"Wong VW, Adams LA, de L\u00e9dinghen V, et al. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"6986_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.clinthera.2021.01.012","volume":"43","author":"S Kogachi","year":"2021","unstructured":"Kogachi S, Noureddin M. Noninvasive evaluation for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Ther. 2021;43(3):455\u201372.","journal-title":"Clin Ther"},{"issue":"3","key":"6986_CR29","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082\u201390.","journal-title":"Hepatology"},{"issue":"2","key":"6986_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/jim-2018-000864","volume":"67","author":"F Bril","year":"2019","unstructured":"Bril F, McPhaul MJ, Caulfield MP, et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med. 2019;67(2):303\u201311.","journal-title":"J Investig Med"},{"issue":"1","key":"6986_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14366\/usg.21076","volume":"41","author":"JK Jang","year":"2022","unstructured":"Jang JK, Choi SH, Lee JS, et al. Accuracy of the ultrasound attenuation coefficient for the evaluation of hepatic steatosis: a systematic review and meta-analysis of prospective studies. Ultrasonography. 2022;41(1):83\u201392.","journal-title":"Ultrasonography"},{"issue":"4","key":"6986_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/cld.740","volume":"13","author":"D Berger","year":"2019","unstructured":"Berger D, Desai V, Janardhan S. Liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease. Clin Liver Dis (Hoboken). 2019;13(4):114\u20136.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"1","key":"6986_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1590\/s0004-2803.202200001-19","volume":"59","author":"MM Concon","year":"2022","unstructured":"Concon MM, Gestic MA, Utrini MP, et al. Should routine liver biopsy be considered in bariatric surgical practice? An analysis of the limitations of non-invasive NAFLD markers. Arq Gastroenterol. 2022;59(1):110\u20136.","journal-title":"Arq Gastroenterol"},{"issue":"2","key":"6986_CR34","doi-asserted-by":"publisher","first-page":"e13446","DOI":"10.1111\/eci.13446","volume":"51","author":"Q Gu","year":"2021","unstructured":"Gu Q, Cen L, Lai J, et al. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease. Eur J Clin Investig. 2021;51(2):e13446.","journal-title":"Eur J Clin Investig"},{"issue":"21","key":"6986_CR35","doi-asserted-by":"publisher","first-page":"11905","DOI":"10.3390\/ijms222111905","volume":"22","author":"S Di Mauro","year":"2021","unstructured":"Di Mauro S, Scamporrino A, Filippello A, et al. Clinical and molecular biomarkers for diagnosis and staging of NAFLD. Int J Mol Sci. 2021;22(21):11905.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"6986_CR36","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467\u201374.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"6986_CR37","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810\u201320.","journal-title":"Hepatology"},{"issue":"6","key":"6986_CR38","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","volume":"116","author":"CA Matteoni","year":"1999","unstructured":"Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413\u20139.","journal-title":"Gastroenterology"},{"issue":"5","key":"6986_CR39","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751\u20139.","journal-title":"Hepatology"},{"key":"6986_CR40","unstructured":"Sergeant ESG. Epitools Epidemiological Calculators [Internet]. Freemantle: Ausvet Pty Ltd. 2018. [cited 2023 Sept 10]. Available from: http:\/\/epitools.ausvet.com.au."},{"issue":"9","key":"6986_CR41","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/liv.12226","volume":"33","author":"S Verma","year":"2013","unstructured":"Verma S, Jensen D, Hart J, et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33(9):1398\u2013405.","journal-title":"Liver Int"},{"issue":"4","key":"6986_CR42","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s11695-014-1183-4","volume":"24","author":"E Cazzo","year":"2014","unstructured":"Cazzo E, de Felice GF, Pareja JC, et al. Nonalcoholic fatty liver disease in morbidly obese subjects: correlation among histopathologic findings, biochemical features, and ultrasound evaluation. Obes Surg. 2014;24(4):666\u20138.","journal-title":"Obes Surg"},{"issue":"7","key":"6986_CR43","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/00004836-200608000-00015","volume":"40","author":"MW Pantsari","year":"2006","unstructured":"Pantsari MW, Harrison SA. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. J Clin Gastroenterol. 2006;40(7):633\u20135.","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl 1","key":"6986_CR44","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98\u2013S110.","journal-title":"Diabetes Care"},{"issue":"6","key":"6986_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Byrne CD, Scorletti E, et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. Diabetes Metab. 2020;46(6):427\u201341.","journal-title":"Diabetes Metab"},{"key":"6986_CR46","doi-asserted-by":"publisher","first-page":"154001","DOI":"10.1016\/j.metabol.2019.154001","volume":"101","author":"G Ranjbar","year":"2019","unstructured":"Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box! Metabolism. 2019;101:154001.","journal-title":"Metabolism"},{"issue":"2","key":"6986_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2174\/1570161117666190405164313","volume":"18","author":"VG Athyros","year":"2020","unstructured":"Athyros VG, Polyzos SA, Kountouras J, et al. Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; New Kids on the Block. Curr Vasc Pharmacol. 2020;18(2):172\u201381.","journal-title":"Curr Vasc Pharmacol"},{"issue":"4","key":"6986_CR48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2174\/1570161116666171205105402","volume":"16","author":"N Katsiki","year":"2018","unstructured":"Katsiki N, Imprialos K, Vlachopoulos C. Arterial stiffness, central haemodynamics and non-alcoholic fatty liver disease: links with cardiovascular risk and effects of drug treatment. Curr Vasc Pharmacol. 2018;16(4):401\u20134.","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"6986_CR49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1570161116666171205110801","volume":"16","author":"VG Athyros","year":"2018","unstructured":"Athyros VG, Katsiki N, Doumas M. Recent news on statins for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis. Curr Vasc Pharmacol. 2018;16(2):104\u20136.","journal-title":"Curr Vasc Pharmacol"},{"key":"6986_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","volume":"71","author":"VG Athyros","year":"2017","unstructured":"Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017;71:17\u201332.","journal-title":"Metabolism"},{"issue":"3","key":"6986_CR51","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jdiacomp.2016.12.006","volume":"31","author":"N Katsiki","year":"2017","unstructured":"Katsiki N, Athyros VG, Mikhailidis DP. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs. J Diabetes Complicat. 2017;31(3):521\u20132.","journal-title":"J Diabetes Complicat"},{"issue":"5","key":"6986_CR52","doi-asserted-by":"publisher","first-page":"e95485","DOI":"10.1371\/journal.pone.0095485","volume":"9","author":"YG Wang","year":"2014","unstructured":"Wang YG, Wang P, Wang B, et al. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2014;9(5):e95485.","journal-title":"PLoS One"},{"issue":"7","key":"6986_CR53","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/ijc.26165","volume":"130","author":"C Wang","year":"2012","unstructured":"Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639\u201348.","journal-title":"Int J Cancer"},{"issue":"4","key":"6986_CR54","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ecl.2016.06.005","volume":"45","author":"F Bril","year":"2016","unstructured":"Bril F, Cusi K. Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin N Am. 2016;45(4):765\u201381.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"10","key":"6986_CR55","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","volume":"58","author":"M Stepanova","year":"2013","unstructured":"Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017\u201323.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"6986_CR56","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/hep.31806","volume":"74","author":"AS Alexopoulos","year":"2021","unstructured":"Alexopoulos AS, Crowley MJ, Wang Y, et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology. 2021;74(3):1220\u201333.","journal-title":"Hepatology"},{"issue":"5","key":"6986_CR57","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1210\/jcem.84.5.5661","volume":"84","author":"P Marceau","year":"1999","unstructured":"Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84(5):1513\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6986_CR58","first-page":"355","volume":"24","author":"FH Luyckx","year":"1998","unstructured":"Luyckx FH, Scheen AJ, Desaive C, et al. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diabetes Metab. 1998;24(4):355\u201361.","journal-title":"Diabetes Metab"},{"issue":"4","key":"6986_CR59","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/0016-5085(94)90235-6","volume":"107","author":"BR Bacon","year":"1994","unstructured":"Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107(4):1103\u20139.","journal-title":"Gastroenterology"},{"issue":"1","key":"6986_CR60","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12944-017-0613-4","volume":"16","author":"SX Du","year":"2017","unstructured":"Du SX, Lu LL, Geng N, et al. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis. Lipids Health Dis. 2017;16(1):228.","journal-title":"Lipids Health Dis"},{"key":"6986_CR61","doi-asserted-by":"publisher","first-page":"934989","DOI":"10.3389\/fmed.2022.934989","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Sun R, Yang S, et al. Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: a systematic review. Front Med (Lausanne). 2022;9:934989.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"6986_CR62","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1478-3231.2011.02488.x","volume":"31","author":"P Manousou","year":"2011","unstructured":"Manousou P, Kalambokis G, Grillo F, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int. 2011;31(5):730\u20139.","journal-title":"Liver Int"},{"issue":"12","key":"6986_CR63","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1007\/s11695-020-05003-3","volume":"30","author":"RN Jesus","year":"2020","unstructured":"Jesus RN, Callejas GH, Concon MM, et al. Prevalence and factors associated with hepatic iron overload in obese individuals undergoing bariatric surgery: a cross-sectional study. Obes Surg. 2020;30(12):4967\u201373.","journal-title":"Obes Surg"},{"issue":"Suppl 2","key":"6986_CR64","first-page":"104","volume":"28","author":"AE Pontiroli","year":"2013","unstructured":"Pontiroli AE, Benetti A, Folini L, et al. Other aspects of bariatric surgery: liver steatosis, ferritin and cholesterol metabolism. Nutr Hosp. 2013;28(Suppl 2):104\u20138.","journal-title":"Nutr Hosp"},{"issue":"7","key":"6986_CR65","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1007\/s11695-022-06103-y","volume":"32","author":"RN de Jesus","year":"2022","unstructured":"de Jesus RN, Callejas GH, David Mendon\u00e7a Chaim F, et al. Roux-en-Y gastric bypass as a treatment for hepatic iron overload: an exploratory study. Obes Surg. 2022;32(7):2438\u201344.","journal-title":"Obes Surg"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-023-06986-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-023-06986-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-023-06986-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:32:26Z","timestamp":1706196746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-023-06986-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6986"],"URL":"https:\/\/doi.org\/10.1007\/s11695-023-06986-5","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}